APLT:NSD-Applied Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 16.61

Change

+0.16 (+0.97)%

Market Cap

USD 0.43B

Volume

0.04M

Average Target Price

USD 39.50 (+137.81%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Company Website : http://www.appliedtherapeutics.com

Address : 545 Fifth Avenue, New York, NY, United States, 10017

Employees : 24

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 51.99

Short Ratio : 12.32

52 Week Low : 13.58

Shorted Shares : 1,604,397

200 Day Moving Average : 20.95

Shorted Shares Previous Month : 1,511,859

50 Day Moving Average : 19.10

Shares Held By Insiders : 206.75%

Short Percentage : 6.00%

Shares Held by Institutions : 61.41%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+10.32 (+6.89%)

 USD59.96B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.19 (+0.55%)

 USD55.89B 20.99 15.27
REGN Regeneron Pharmaceuticals, Inc

+4.12 (+0.86%)

 USD51.11B 15.63 12.19
ALXN Alexion Pharmaceuticals, Inc

+1.56 (+1.01%)

 USD33.80B 56.52 33.71
BNTX BioNTech SE

+2.96 (+2.28%)

 USD31.31B -99,999.99 N/A
BGNE BeiGene, Ltd

+0.34 (+0.11%)

 USD28.62B N/A N/A
SGEN Seagen Inc

+3.31 (+2.35%)

 USD25.54B 41.81 34.88
RPRX Royalty Pharma plc

+0.69 (+1.67%)

 USD25.15B 22.60 15.33
GMAB Genmab A/S

+0.02 (+0.06%)

 USD22.68B 26.59 3.21
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing APLT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.53% 16% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.53% 16% F 8% F
Trailing 12 Months  
Capital Gain -59.09% 4% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.09% 4% F 2% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 47.04% 76% C 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.04% 76% C 86% B
Risk Return Profile  
Volatility (Standard Deviation) 112.72% 22% F 12% F
Risk Adjusted Return 41.73% 68% D+ 64% D
Market Capitalization 0.43B 52% F 47% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.18 46% F 34% F
Price / Cash Flow Ratio -5.47 39% F 69% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -164.06% 15% F 7% F
Return on Invested Capital -163.41% 8% F 4% F
Return on Assets -77.23% 6% F 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 12.32 7% F 3% F
Short Percent 9.30% 35% F 23% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.